Exclusive articles:
XFOR: Update on Phase 2 CN Trial at ASH 2023
By David Bautz, PhD
NASDAQ:XFOR
READ THE FULL XFOR RESEARCH REPORT
Business Update
Case Studies of First Three Patients from Phase 2 CN Trial Presented at ASH 2023
On...
FMST: Lithium Prices Decline Creating Potential for Low Cost Entry Points in North American Hard-Rock Lithium Junior Mining Companies
By Steven Ralston, CFA
NASDAQ:FMSTCSE:FAT
From the beginning of 2021 and the end of 2022, the price of lithium skyrocketed over 900% as the transition to...
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
By David Bautz, PhD
OTC:MSCLF
READ THE FULL MSCLF RESEARCH REPORT
Business Update
AAK1 Disclosed as Drug Target for DMD Program
On November 14, 2023, Satellos Biosciences Inc. (OTC:MSCLF)...
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn
By David Bautz, PhD
NASDAQ:BCLI
READ THE FULL BCLI RESEARCH REPORT
Business Update
Clear Path Forward for Phase 3b Trial of NurOwn
On December 7, 2023, BrainStorm Cell Therapeutics,...
CVM: NICE To Have Your Support
By John Vandermosten, CFA
NYSE:CVM
READ THE FULL CVM RESEARCH REPORT
Multikine Selected as Potential New Standard of Care
CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this...
